Navigation Links
LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

oximately $0.03 in the current quarter. Prior year fourth quarter diluted net income per share included approximately $0.01 of tax benefit resulting from legislation enacted by Congress in December 2006 which retroactively reinstated the research and development tax credit. As a result, in 2006 the Company recognized the full-year tax benefit of its research and development tax credits in the fourth quarter, whereas in 2007 the benefit was recognized throughout the year.

Full Year 2007 Results

Product revenues for full year 2007 were $190.5 million, up 35%, compared to $140.6 million in 2006. AlloDerm(R) product revenues increased 40% to $167.1 million compared to $119.4 million in the prior year. Orthopedic product revenues increased 27% to $12.3 million in the year from $9.7 million in 2006. Repliform(R) revenues were $7.8 million compared to $8.1 million in 2006.

Operating income increased 30% to $43.4 million in 2007 compared to $33.3 million in 2006.

Net income for 2007 was $26.9 million, or $0.78 per diluted share, compared to net income of $20.5 million, or $0.60 per diluted share income in the prior year.

LifeCell's balance sheet remains strong with $97.9 million of cash and investments and no debt at December 31, 2007. During 2007, the Company generated cash flow from operating activities of $29.2 million, offset by $12.4 million of cash used for capital expenditures.

Full Year 2008 Financial Outlook

As previously announced, the Company is projecting product revenues for 2008 in the range of $233.0 million to $243.0 million, which represents expected annualized growth between 22% and 28% compared with 2007 product revenues of $190.5 million. The Company expects its product revenue mix in 2008 to be approximately 90% reconstructive, 7% orthopedic and 3% urogynecology. The Company is projecting 2008 operating income in the range of $57.0 million to $62.0 million, with diluted net income per share projected to b
'/>"/>

SOURCE LifeCell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
2. AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance
3. DATATRAK International Reports Fourth Quarter and Full Year Results for 2007
4. Claimsnet.com Reports Fiscal Year 2007 Results
5. Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
6. Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results
7. 012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007
8. HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007
9. NHP Reports Fourth Quarter and Full Year 2007 Earnings
10. High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter
11. Clarity for Consumers on Botox Complication and Death Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Washington, DC (PRWEB) April 21, 2015 ... operations and Information Technology advisory firm that helps ... technological change, today announced that the Association ... Optimity a Preferred Vendor. ACAP represents 58 local, ... serve more than 13 million people primarily enrolled ...
(Date:4/21/2015)... FL (PRWEB) April 21, 2015 AxoGen, ... on the peripheral nerve repair market, will report results ... 5, 2015 following the close of the market. ... webcast for the investment community following the release at ... phone are invited to call toll free at 1.877.407.0993 ...
(Date:4/21/2015)... April 21, 2015 The PracticeMatch Career ... 5:00 to 8:00 pm at the William and Ida Friday ... NC 27599. More than 50 hospitals, clinics and groups with ... specialties will be represented. Attendees will enjoy free hors d’oeuvres ... Fairs for PracticeMatch says “Chapel Hill is an ...
(Date:4/21/2015)... With a growing number of Americans retiring abroad, ... international political instability and terrorism top the list of ... a global insurance provider with 68 years’ experience covering ... citizenship, also found strong concern but lack of information ... overseas . , Asked to choose the risks of ...
(Date:4/21/2015)... Pharmacy point of sale software ... Independent Pharmacy Cooperative trade show, to be held April ... , Retail Management Solutions recently became an approved vendor ... Gross, VP of Sales and Marketing. Gross says that ... trade shows in the country -- and this new ...
Breaking Medicine News(10 mins):Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2Health News:AxoGen, Inc. to Report First Quarter Financial Results on May 5, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 2Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 3Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 2Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 3
... 30 Neogen Corporation,(Nasdaq: NEOG ) announces the following Webcast: , ... When: Tuesday, January 6, 2009 @ 11:00 EST, ... Live over the Internet -- Simply log on to the web at ... above., Contact: Terry Maynard of Neogen Corporation, +1-800-234-5333., , ...
... called "the world,s first disposable hearing aid", and is designed ... needing part-time hearing assistance. , ... ... being called "the world,s first disposable hearing aid", and is ...
... impulsive people, New Year,s resolutions often include being ... on dangerous behavior, such as drug use. But ... as novelty seekers by psychologists--face an uphill battle ... the way their brains process dopamine. The research ...
... YORK and BIRMINGHAM, Ala., Dec. 29 Health,Systems Solutions, Inc. ... ) today announced that they have agreed to extend the ... "We are pleased that, with the ... timetable for the completion of the merger and we are ...
... Dec. 29 Curious about your child,s diet,preventing ... or daughter has a sports-related,injury? , ... youth sports coaches, parents and,athletes focused on education, ... Spine (PEAKOrthopedics.com) to answer these questions,through an online, ...
... have lower risks of Alzheimer,s disease and other cognitive ... In more than half of the studies, published since ... had lower dementia risks than nondrinkers. In only a ... a two-edged sword," said Michael Collins, Ph.D., a professor ...
Cached Medicine News:Health News:Supple, Hi-Flex Cable from Cicoil Makes First Disposable Hearing Aid Possible 2Health News:Risk takers, drug abusers driven by decreased ability to process dopamine 2Health News:Health Systems Solutions and Emageon Extend Merger Closing 2Health News:Health Systems Solutions and Emageon Extend Merger Closing 3Health News:SportZu.tv Partners With PEAK Orthopedics & Spine to Launch an Online Sports Doctor's Office 2Health News:Moderate drinking can reduce risks of Alzheimer's dementia and cognitive decline 2
(Date:4/21/2015)... 2015 EUSA Pharma (EUSA), a ... announced the appointment of Lee Morley as ... Non-Executive Director.  Bryan Morton, who established EUSA Pharma as ... Lee Morley joins from Jazz ... of Commercial for Europe and ...
(Date:4/20/2015)... KUALA LUMPUR, Malaysia , April 20, 2015 /PRNewswire/ ... 2015, resulting in a scarcity of opportunities for generic ... drug manufacturers in the region are looking beyond the ... the quality of existing drugs. Certain established generic manufacturers ... research and development of new molecules, although the impact ...
(Date:4/20/2015)... , April 20, 2015 This report analyzes the ... following Product Segments: Non-Powered Breast Pumps, and Powered Breast Pumps. ... Canada , Japan , ... Rest of World. Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
Breaking Medicine Technology:EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 2EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 2Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 4Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 5World Breast Pumps Industry 2World Breast Pumps Industry 3World Breast Pumps Industry 4World Breast Pumps Industry 5World Breast Pumps Industry 6World Breast Pumps Industry 7World Breast Pumps Industry 8World Breast Pumps Industry 9World Breast Pumps Industry 10World Breast Pumps Industry 11World Breast Pumps Industry 12World Breast Pumps Industry 13World Breast Pumps Industry 14
... NEW YORK, Oct. 6 Reportlinker.com announces ... available in its catalogue. , ... Pharma and Biotech , ... The Drug Delivery Partnering Agreements in Pharma ...
... N.J., Oct. 6 Centocor Ortho Biotech Inc. and ... the European Commission has approved SIMPONI(TM) (golimumab) as a ... rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) ... In the European Union, SIMPONI is approved as a ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 2Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 3Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 4Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 5Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 6Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 2SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 5SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 6SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 8SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 9SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 10
... to introduce the Cmax operating table that ... general surgical table with the radiolucence and ... it the most advanced, versatile surgical table ... designed to support advancements in surgical procedures ...
... urology imaging table is a fully digital ... imaging and advanced patient data management system. ... in the industry providing unsurpassed access for ... changed to either a right- or left- ...
Inquire...
... Elevated Immunosuppressant Control is a bilevel Cyclosporine ... This unique product is ideal for use ... Cyclosporine levels, such as C2 monitoring, which ... two hours post-dose., ,Lyphochek Elevated Immunosuppressant Control ...
Medicine Products: